Introduction
============

Colorectal cancer (CRC) remains the third most commonly diagnosed cancer in males and the second in females, with an estimated 1.4 million cases and 693,900 deaths occurring worldwide in 2012.[@b1-ott-9-3307] Although the 5-year survival rate for patients with localized CRC approaches 90%, the rate for patients with distant metastatic CRC is 13%.[@b2-ott-9-3307] In most cases, the mortality is caused by liver metastasis.

Recently, the role of chemokines in cancer metastasis has been highlighted. Target organs produce and release specific chemokines that attract distant cancer cells carrying specific chemokine receptors.[@b3-ott-9-3307],[@b4-ott-9-3307] The C-X-C chemokine receptor type 4 (CXCR4) and its chemokine ligand 12 (CXCL12) are two key factors in the cross talk between cancer cells and their microenvironment, which makes them promising targets for cancer therapy.[@b5-ott-9-3307]

CXCR4 overexpression is known to occur in \>20 human tumor types, including ovarian,[@b6-ott-9-3307] prostate,[@b7-ott-9-3307] esophageal,[@b8-ott-9-3307] melanoma,[@b9-ott-9-3307] and renal cell carcinoma.[@b10-ott-9-3307] CXCR4 expression is also shown to promote angiogenesis, which has been shown to be critical for cancer cell survival in previous studies.[@b11-ott-9-3307],[@b12-ott-9-3307] Furthermore, preclinical studies using several types of cancer models demonstrated that directed metastasis of cancer cells is mediated by CXCR4 activation and migration of cancer cells toward CXCL12-expressing organs, including bone marrow, liver, lungs, and lymph nodes.[@b13-ott-9-3307]--[@b15-ott-9-3307]

Several retrospective studies have demonstrated that high CXCR4 expression in cancer specimens is associated with a poor prognosis in several human tumor types.[@b16-ott-9-3307]--[@b18-ott-9-3307] Specifically, CXCR4 expression in primary CRC had significant association with recurrence, survival, and liver metastasis in a retrospective study in CRC patients.[@b17-ott-9-3307] Most of the studies demonstrating the role of CXCR4 expression as a prognostic factor inspected tumor tissue and CXCR4 levels. However, whether serum CXCR4 levels in metastatic or recurrent CRC have a prognostic role have not been evaluated. Here, we examine serum specimens from patients with CRC to resolve whether serum CXCR4 levels can be a significant prognostic factor for patients with metastatic or recurrent CRC.

Materials and methods
=====================

Study population
----------------

From March 2008 to July 2011, blood samples from 65 patients with newly diagnosed metastatic or recurrent CRC were collected, and we reviewed the data of these patients thereafter. We analyzed serum samples from 55 patients after excluding patients with a decreased sample volume or who had already started treatment before the blood samples were obtained. All the samples used in analysis were collected before starting a novel treatment. After collection, the samples were kept at room temperature for 2 hours to allow clotting and then were immediately centrifuged (1,000 × *g*) for 15 minutes at 4°C and were then cryopreserved at −80°C.

The study was approved by the Korea University Anam Hospital Institutional Review Board, and written informed consent was obtained from each participant.

Analysis of CXCR4 plasma levels
-------------------------------

The level of plasma CXCR4 was quantified using a commercially available ELISA kit (soluble Human CXC-chemokine Receptor 4 ELISA Kit; Cusabio Biotech Co. Ltd., Wuhan, People's Republic of China). The detailed procedure of this 4.5-hour solid-phase ELISA was as follows. One hundred microliters of standard and sample were added to each well and incubated for 2 hours at 37°C. This step was followed by the addition of 100 µL of biotin antibody to each well and incubation for 1 hour at 37°C, and then each well was aspirated and washed three times. Horseradish peroxidase-avidin (100 µL) conjugate was added to each well, and the plates were incubated for 1 hour at 37°C, and subsequently the aspiration/wash process was performed five times. Tetramethylbenzidine (TMB) substrate (90 µL) was added to each well, and the plates were incubated for 30 minutes at 37°C and protected from light. Stop solution (50 µL) was then added to each well. The optical density of each well was determined using a niMARK™ microplate reader (Bio-Rad Laboratories Inc., Hercules, CA, USA) at 450 nm and wavelength correction was performed at 540 nm. All the serum samples were measured three times, and the mean level of the measurements was used for analysis.

Statistical analysis
--------------------

Statistical analyses were carried out using IBM SPSS Statistics Version 20.0 (IBM Corporation, Armonk, NY, USA). Normality of distribution was tested using the Shapiro--Wilks' *W*-test, and statistical significances of differences were tested using independent *t*-tests. If the groups were not normally distributed, the Mann--Whitney *U*-test was applied. Since there was no reference range available for serum CXCR4 levels, we chose the level by using receiver operating characteristic (ROC) curves for predicting 2-year survival rate. Survival analyses were performed using Kaplan--Meier survival analysis and the Cox's proportional hazards model. Univariate analysis was performed to identify several prognostic factors of CRC patients by Kaplan--Meier survival analysis, and the *P*-value was calculated by the log-rank test. Multivariate analysis of meaningful parameters was performed with the Cox regression model. The results were considered statistically significant if *P*\<0.05.

Results
=======

Patient characteristics
-----------------------

A total of 55 advanced CRC patients were analyzed. Baseline characteristics are presented in [Table 1](#t1-ott-9-3307){ref-type="table"}. Of note, patients were predominantly male (63.6%) with the median age of 62 years (range: 39--82), and 85.5% of the patients had metastatic disease. More than half of the patients had undergone palliative surgery, and liver metastases were observed in 67.3% of the patients. Forty-five percent of patients had mutant KRAS and all patients received two or more lines of chemotherapy. The median serum CXCR4 level of all enrolled patients was 271.76 pg/mL (range: 56.52--860.10).

Serum CXCR4 level according to clinical features
------------------------------------------------

Age, sex, disease status (metastatic or recurrent), surgery, location, and tissue KRAS mutation status did not influence the serum CXCR4 levels ([Table 2](#t2-ott-9-3307){ref-type="table"}).

The median serum CXCR4 level from patients with two or more metastatic sites was 315.10 pg/mL, while that from patients with one or no metastatic site was 224.86 pg/mL. The difference was statistically significant (*P*=0.011). The median serum CXCR4 level from patients with liver metastasis was significantly higher than that from patients with no liver metastasis (321.76 and 222.24 pg/mL, respectively; *P*=0.033). Additionally, there was a meaningful difference with regard to the influence of CA 19-9 levels on serum CXCR4 levels. The median serum CXCR4 level from patients with abnormally high CA 19-9 levels (\>37 IU/mL) was 351.76 pg/mL, while that from patients with normal CA 19-9 levels (≤37 IU/mL) was 240.45 pg/mL (*P*=0.037; [Table 2](#t2-ott-9-3307){ref-type="table"}).

Survival
--------

The median follow-up time for all patients, estimated by the reverse Kaplan--Meier method, was 44.67 months. The median overall survival (OS) of all CRC patients was 19.53 months (95% confidence interval \[CI\]: 15.90--23.16) ([Figure 1](#f1-ott-9-3307){ref-type="fig"}). The results of univariate analysis are shown in [Table 3](#t3-ott-9-3307){ref-type="table"}. Sex, age, disease status, location of primary site, number of metastatic sites, CA 19-9 level, and tissue KRAS mutation status failed to show any relation to survival. However, liver metastasis was an excellent predictor of outcome. The median OS of patients with liver metastasis was 18.37 months (95% CI: 14.88--21.86), while that of patients without liver metastasis was 29.63 months (*P*=0.033). Additionally, patients who had undergone palliative surgery had a better prognosis than patients who had not undergone palliative surgery (23.93 and 16.20 months, respectively; *P*=0.036).

We also sought to identify whether serum CXCR4 levels could predict prognosis. The advanced CRC patients were regrouped according to their serum CXCR4 levels. The best cutoff value of serum CXCR4 level was set up as 240.45 pg/mL (area under the ROC curve \[AUC\] 0.65, sensitivity 0.697, 1-specificity 0.591) using ROC curves to predict 2-year survival. The median OS of the patients with a relatively higher serum CXCR4 level (≥240.45 pg/mL) was 17.03 months (95% CI: 14.67--19.39), whereas that of patients with a relatively lower serum CXCR4 level (\<240.45 pg/mL) were 26.50 months (95% CI: 17.37--35.63). The Kaplan--Meier survival curve according to serum CXCR4 level is shown in [Figure 2](#f2-ott-9-3307){ref-type="fig"}, and this difference was statistically significant (*P*=0.046).

Multivariate analysis of meaningful parameters was performed with the Cox regression model ([Table 4](#t4-ott-9-3307){ref-type="table"}). Liver metastasis and palliative surgery showed statistically significant differences. The hazard ratio of the liver metastasis was 2.114 (95% CI: 1.067--4.191; *P*=0.032) and that of the palliative surgery was 0.456 (95% CI: 0.239--0.870; *P*=0.017). However, serum CXCR4 levels failed to show a statistical significance in the multivariate analysis (*P*=0.239).

Discussion
==========

CXCR4, originally named LESTR or fusin, is a G-protein-coupled chemokine receptor.[@b19-ott-9-3307] It exerts its biological effect by binding to its ligand CXCL12 (previously termed stromal cell-derived factor 1),[@b20-ott-9-3307],[@b21-ott-9-3307] activating the downstream protein kinase B (AKT)/mitogen-activated protein kinases (MAPKs) signaling pathway.[@b7-ott-9-3307] Intense in vitro research implicated CXCR4 in numerous cancer-specific metastases including breast,[@b3-ott-9-3307] colon,[@b22-ott-9-3307] lung,[@b23-ott-9-3307] kidney,[@b24-ott-9-3307] melanoma,[@b25-ott-9-3307],[@b26-ott-9-3307] and prostate cancer.[@b7-ott-9-3307] A growing body of evidence indicated that directed metastasis of cancer cells was mediated by CXCR4 activation toward a concentration gradient of CXCL12. CXCL12 expression levels are high in the liver, lung, and bone marrow, making them common metastasis sites.

Several retrospective studies demonstrated that high CXCR4 expression in cancer specimens is associated with a poor prognosis in several human tumor types.[@b16-ott-9-3307]--[@b18-ott-9-3307] Specifically, one study suggested that high expression of CXCR4 in tumor specimens from early-stage CRC patients was associated with an increased risk of locoregional recurrence and/or liver metastasis, and that high CXCR4 expression in primary tumor specimens from metastatic CRC patients correlated with worse overall median survival.[@b27-ott-9-3307] Most of these studies have been conducted in tissue specimens. Few studies have reported serum CXCR4 levels, although one study counted CXCR4-positive circulating endothelial cells and demonstrated that CXCR4-positive circulating endothelial cell levels may predict the prognosis of bevacizumab combination chemotherapy.[@b28-ott-9-3307] No current study has presented direct serum levels of CXCR4 in CRC.

As the initial report of clinical utility of serum CXCR4 levels, our study may serve as a basis for determining the ranges of low or high serum CXCR4 levels for metastatic CRC patients. In this study, serum CXCR4 levels were positively correlated with more metastatic sites, liver metastasis, and an abnormal level of CA 19-9, implying that serum CXCR4 levels may be associated with tumor burden. These findings suggest that CXCR4 expression may promote tumor metastases. A previous in vitro study that demonstrated the role of CXCR4 in metastases supports this suggestion.[@b22-ott-9-3307]

Another important result of our study was that serum CXCR4 levels were associated with a patient's prognosis. Liver metastases and metastatic burden are a powerful predictor of survival, and serum CXCR4 levels properly reflect liver metastasis and metastatic burden. Thus, we could assume that the serum CXCR4 levels may be a useful prognostic factor. In univariate analysis, serum CXCR4 level was a statistically significant predictor of survival in metastatic CRC patients. In multivariate analysis, however, serum CXCR4 levels lose statistical power, and the only meaningful factors were liver metastasis and no surgery. This may be caused by small sample size or multiple collinearity between liver metastasis and CXCR4 level.

Recent use of antagonist peptides to the CXCR4 receptor has shown promise for future therapeutic strategies that may allow control of tumor spread by blocking the CXCR4 receptor.[@b29-ott-9-3307],[@b30-ott-9-3307] Additionally, CXCR4 level was shown to be correlated with VEGF level in a previous study investigating osteosarcoma,[@b31-ott-9-3307] and CXCR4-positive circulating endothelial cells were correlated with the prognosis of bevacizumab, a VEGF monoclonal antibody in the CRC patients.[@b28-ott-9-3307] Further evaluation is needed to verify the role of serum CXCR4 level as a predictive marker for CXCR4 antagonists or VEGF inhibitors.

There are some limitations of this study. First, the number of study samples was relatively small. Also, serum CXCR4 levels of healthy control subjects and early-stage CRC patients were not assessable. For this reason, we could not compare serum CXCR4 levels of metastatic CRC patients with healthy subjects and early-stage CRC patients. Thus, the role of CXCR4 in tumorigenesis and progression of localized cancer stage could not be fully investigated. Next, this study could not verify the role of serum CXCR4 as a predictive marker of bevacizumab because we did not examine VEGF levels and the number of patients receiving bevacizumab was only six of the 55 patients.

Conclusion
==========

The results of this study suggest that serum CXCR4 levels are strongly associated with the number of metastatic sites and liver metastasis in advanced CRC. In addition, serum CXCR4 levels may be a possible prognostic marker in metastatic/recurrent CRC. To clarify the role of serum CXCR4 as a definite prognostic marker and predictive marker for bevacizumab, future studies of molecular mechanisms and the correlation with CXCR4 and VEGF expression in cancer tissues are needed with large samples.
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###### 

Patients' clinical and disease characteristics

  Variables                             No of patients (N=55)    \% of patients
  ------------------------------------- ------------------------ ----------------
  Age, median (range) (years)           62 (39--82)              
   ≤65                                  40                       72.7
   \>65                                 15                       27.3
  Sex                                                            
   Male                                 35                       63.6
   Female                               20                       36.4
  Disease status                                                 
   Metastatic                           47                       85.5
   Recurrent                            8                        14.5
  Palliative surgery                                             
   Yes                                  36                       65.5
   No                                   19                       34.5
  Primary site                                                   
   Colon                                39                       70.9
   Rectum                               16                       29.1
  No of metastatic sites                                         
   0--1                                 13                       23.6
   ≥2                                   42                       76.4
  Liver metastasis                                               
   Yes                                  37                       67.3
   No                                   18                       32.7
  *KRAS*                                                         
   Mutant                               25                       45.5
   Wild type                            30                       54.5
  CA 19-9                                                        
   ≤37 IU/mL                            36                       65.5
   \>37 IU/mL                           19                       34.5
  Chemotherapy                                                   
   First line                           55                       100.0
   Second line                          55                       100.0
   Third or more line                   39                       70.9
  CXCR4 level, median (range) (pg/mL)   271.76 (56.52--860.10)   

**Abbreviation:** CXCR4, C-X-C chemokine receptor type 4.

###### 

Comparison of the median serum CXCR4 levels according to clinical features

  Variables                     No of patients (N=55)   Median CXCR4 level (pg/mL)   *P*-value
  ----------------------------- ----------------------- ---------------------------- -----------
  Age, median (range) (years)   62 (39--82)                                          
   ≤65                          40                      277.36                       0.424
   \>65                         15                      271.05                       
  Sex                                                                                
   Male                         35                      246.29                       0.351
   Female                       20                      326.40                       
  Disease status                                                                     
   Metastatic                   47                      271.76                       0.467
   Recurrent                    8                       273.67                       
  Palliative surgery                                                                 
   Yes                          36                      250.33                       0.502
   No                           19                      301.05                       
  Primary site                                                                       
   Colon                        39                      310.74                       0.646
   Rectum                       16                      287.55                       
  No of metastatic sites                                                             
   0--1                         13                      224.86                       0.011
   ≥2                           42                      315.10                       
  Liver metastasis                                                                   
   Yes                          37                      321.76                       0.033
   No                           18                      222.24                       
  Tissue *KRAS*                                                                      
   Mutant                       25                      248.43                       0.589
   Wild type                    30                      292.0                        
  CA 19-9                                                                            
   ≤37 IU/mL                    36                      240.45                       0.037
   \>37 IU/mL                   19                      351.76                       

**Abbreviation:** CXCR4, C-X-C chemokine receptor type 4.

###### 

Prognostic factors for OS in univariate analysis (N=55)

  Variables                Median OS (months)   95% CI          *P*-value
  ------------------------ -------------------- --------------- -----------
  Sex                                                           
   Male                    17.03                12.71--21.353   0.529
   Female                  19.53                9.45--29.61     
  Age (years)                                                   
   ≤65                     18.37                14.81--21.93    0.365
   \>65                    23.93                13.24--34.62    
  Disease status                                                
   Metastatic              20.33                15.98--24.68    0.728
   Recurrent               17.03                15.37--18.69    
  Primary site                                                  
   Colon                   20.33                16.37--18.10    0.585
   Rectum                  16.20                14.30--23.23    
  No of metastatic sites                                        
   0--1                    18.37                2.33--34.41     0.322
   ≥2                      19.53                15.05--24.01    
  Liver metastasis                                              
   Yes                     18.37                14.88--21.86    0.033
   No                      29.63                20.58--38.68    
  Palliative surgery                                            
   Yes                     23.93                15.93--31.93    0.036
   No                      16.20                11.79--20.61    
  CA 19-9                                                       
   ≤37 IU/mL               20.90                12.01--29.79    0.120
   \>37 IU/mL              17.40                9.91--24.89     
  Tissue *KRAS*                                                 
   Mutant                  18.37                14.40--22.34    0.281
   Wild type               20.90                11.51--30.29    
  CXCR4                                                         
   ≤240.45 pg/mL           26.50                17.37--35.63    0.046
   \>240.45 pg/mL          17.03                14.67--19.39    

**Abbreviations:** CI, confidence interval; CXCR4, C-X-C chemokine receptor type 4; OS, overall survival.

###### 

Prognostic factors for OS in multivariate analysis (N=55)

  Variables            Hazard ratio   95% CI         Multivariate *P*-value
  -------------------- -------------- -------------- ------------------------
  Liver metastasis                                   
   Yes                 2.114          1.067--4.191   0.032
   No                                                
  Palliative surgery                                 
   Yes                 0.456          0.239--0.870   0.017
   No                                                
  CXCR4                                              
   ≤240.45 pg/mL       1.451          0.781--2.694   0.239
   \>240.45 pg/mL                                    

**Abbreviations:** CI, confidence interval; CXCR4, C-X-C chemokine receptor type 4; OS, overall survival.
